AKT1 and hepatocellular carcinoma: The combination of 3-HAA and sorafenib was demonstrated to sensitize hepatocellular carcinoma (HCC) cells by upregulation of phosphatases PPP1R15A/DUSP6 which reduced AKT phosphorylation and activity [20].